Overall Responder

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) presented positive results from its Phase 3 study of plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C). In two large studies, Synergy examined plecanatide, marketed as "Trulance," in both 3 mg and 6 mg doses....